Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial

Ross A Soo, Sanjay Popat, Urania Dafni, Adrianus Johannes de Langen, Ernest Nadal, Patricia Iranzo, Martin Früh, Maurice Pérol, Giulio Metro, Maria Angeles Sala, Marc Cucurull Salamero, Ferdinando Cerciello, Alfredo Addeo, Manuel Dómine, Youssef Oulkhouir, Nicolas Cloarec, Rafael López Castro, Patrizia Froesch, Heidi Roschitzki-Voser, Barbara Ruepp, Adriana Gasca-Ruchti, Tereza Dellaporta, Solange Peters, Rolf A Stahel, Ross A Soo, Sanjay Popat, Rolf A Stahel, Solange Peters, Urania Dafni, Bartomeu Massuti, Martin Früh, Maurice Pérol, Giulio Metro, Joop de Langen, Anita Hiltbrunner, Barbara Ruepp, Rosita Kammler, Heidi Roschitzki-Voser, Sabin Allemann, Manuela Akaltan, Sonja Brülisauer, Adriana Gasca-Ruchti, Nino Giacomelli, Eva Grolimund, Uli Kodjadjiku, Sandra Kulli, Tanja Mombelli, Suganiya Nagarajan, Lionel Nobs, Manuel Papparella, Anne-Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Thomas Sasse, Susanne Roux, Mirjam Schneider, Sandra Troesch, Patrick Vagenknecht, Michael Wiedemann, Zoi Tsourti, Georgia Dimopoulou, Panagiota Zygoura, Katerina Vervita, Tereza Dellaporta, Maria Fernández, Laura Benito, Sara Busquet, Eva Pereira, Zuzsanna Maniecka Moser, Priska Rentsch, Youssef Oulkhouir, Nicolas Cloarec, Pier Luigi Piovano, Ernest Nadal, Patricia Iranzo, Maria Angeles Sala, Marc Cucurull Salamero, Manuel Dómine, Rafael López Castro, Joaquín Mosquera Martínez, Ferdinando Cerciello, Alfredo Addeo, Patrizia Froesch, Adrienne Bettini

Open source

DOI: 10.1016/s2213-2600(26)00203-1
Published: 2026-10
Container: The Lancet Respiratory Medicine
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2213-2600-26-00203-1,
  title = {Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial},
  author = {Ross A Soo and Sanjay Popat and Urania Dafni and Adrianus Johannes de Langen and Ernest Nadal and Patricia Iranzo and Martin Früh and Maurice Pérol and Giulio Metro and Maria Angeles Sala and Marc Cucurull Salamero and Ferdinando Cerciello and Alfredo Addeo and Manuel Dómine and Youssef Oulkhouir and Nicolas Cloarec and Rafael López Castro and Patrizia Froesch and Heidi Roschitzki-Voser and Barbara Ruepp and Adriana Gasca-Ruchti and Tereza Dellaporta and Solange Peters and Rolf A Stahel and Ross A Soo and Sanjay Popat and Rolf A Stahel and Solange Peters and Urania Dafni and Bartomeu Massuti and Martin Früh and Maurice Pérol and Giulio Metro and Joop de Langen and Anita Hiltbrunner and Barbara Ruepp and Rosita Kammler and Heidi Roschitzki-Voser and Sabin Allemann and Manuela Akaltan and Sonja Brülisauer and Adriana Gasca-Ruchti and Nino Giacomelli and Eva Grolimund and Uli Kodjadjiku and Sandra Kulli and Tanja Mombelli and Suganiya Nagarajan and Lionel Nobs and Manuel Papparella and Anne-Christine Piguet and Sabrina Ribeli-Hofmann and Virginia Rodriguez Martinez and Thomas Sasse and Susanne Roux and Mirjam Schneider and Sandra Troesch and Patrick Vagenknecht and Michael Wiedemann and Zoi Tsourti and Georgia Dimopoulou and Panagiota Zygoura and Katerina Vervita and Tereza Dellaporta and Maria Fernández and Laura Benito and Sara Busquet and Eva Pereira and Zuzsanna Maniecka Moser and Priska Rentsch and Youssef Oulkhouir and Nicolas Cloarec and Pier Luigi Piovano and Ernest Nadal and Patricia Iranzo and Maria Angeles Sala and Marc Cucurull Salamero and Manuel Dómine and Rafael López Castro and Joaquín Mosquera Martínez and Ferdinando Cerciello and Alfredo Addeo and Patrizia Froesch and Adrienne Bettini},
  year = {2026},
  journal = {The Lancet Respiratory Medicine},
  doi = {10.1016/s2213-2600(26)00203-1},
  url = {https://doi.org/10.1016/s2213-2600(26)00203-1}
}

RIS

TY  - JOUR
TI  - Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial
AU  - Ross A Soo
AU  - Sanjay Popat
AU  - Urania Dafni
AU  - Adrianus Johannes de Langen
AU  - Ernest Nadal
AU  - Patricia Iranzo
AU  - Martin Früh
AU  - Maurice Pérol
AU  - Giulio Metro
AU  - Maria Angeles Sala
AU  - Marc Cucurull Salamero
AU  - Ferdinando Cerciello
AU  - Alfredo Addeo
AU  - Manuel Dómine
AU  - Youssef Oulkhouir
AU  - Nicolas Cloarec
AU  - Rafael López Castro
AU  - Patrizia Froesch
AU  - Heidi Roschitzki-Voser
AU  - Barbara Ruepp
AU  - Adriana Gasca-Ruchti
AU  - Tereza Dellaporta
AU  - Solange Peters
AU  - Rolf A Stahel
AU  - Ross A Soo
AU  - Sanjay Popat
AU  - Rolf A Stahel
AU  - Solange Peters
AU  - Urania Dafni
AU  - Bartomeu Massuti
AU  - Martin Früh
AU  - Maurice Pérol
AU  - Giulio Metro
AU  - Joop de Langen
AU  - Anita Hiltbrunner
AU  - Barbara Ruepp
AU  - Rosita Kammler
AU  - Heidi Roschitzki-Voser
AU  - Sabin Allemann
AU  - Manuela Akaltan
AU  - Sonja Brülisauer
AU  - Adriana Gasca-Ruchti
AU  - Nino Giacomelli
AU  - Eva Grolimund
AU  - Uli Kodjadjiku
AU  - Sandra Kulli
AU  - Tanja Mombelli
AU  - Suganiya Nagarajan
AU  - Lionel Nobs
AU  - Manuel Papparella
AU  - Anne-Christine Piguet
AU  - Sabrina Ribeli-Hofmann
AU  - Virginia Rodriguez Martinez
AU  - Thomas Sasse
AU  - Susanne Roux
AU  - Mirjam Schneider
AU  - Sandra Troesch
AU  - Patrick Vagenknecht
AU  - Michael Wiedemann
AU  - Zoi Tsourti
AU  - Georgia Dimopoulou
AU  - Panagiota Zygoura
AU  - Katerina Vervita
AU  - Tereza Dellaporta
AU  - Maria Fernández
AU  - Laura Benito
AU  - Sara Busquet
AU  - Eva Pereira
AU  - Zuzsanna Maniecka Moser
AU  - Priska Rentsch
AU  - Youssef Oulkhouir
AU  - Nicolas Cloarec
AU  - Pier Luigi Piovano
AU  - Ernest Nadal
AU  - Patricia Iranzo
AU  - Maria Angeles Sala
AU  - Marc Cucurull Salamero
AU  - Manuel Dómine
AU  - Rafael López Castro
AU  - Joaquín Mosquera Martínez
AU  - Ferdinando Cerciello
AU  - Alfredo Addeo
AU  - Patrizia Froesch
AU  - Adrienne Bettini
PY  - 2026
JO  - The Lancet Respiratory Medicine
DO  - 10.1016/s2213-2600(26)00203-1
UR  - https://doi.org/10.1016/s2213-2600(26)00203-1
ER  -

APA

Soo, R. A., Popat, S., Dafni, U., Langen, A. J. D., Nadal, E., Iranzo, P., Früh, M., Pérol, M., Metro, G., Sala, M. A., Salamero, M. C., Cerciello, F., Addeo, A., Dómine, M., Oulkhouir, Y., Cloarec, N., Castro, R. L., Froesch, P., Roschitzki-Voser, H., Ruepp, B., Gasca-Ruchti, A., Dellaporta, T., Peters, S., Stahel, R. A., Soo, R. A., Popat, S., Stahel, R. A., Peters, S., Dafni, U., Massuti, B., Früh, M., Pérol, M., Metro, G., Langen, J. D., Hiltbrunner, A., Ruepp, B., Kammler, R., Roschitzki-Voser, H., Allemann, S., Akaltan, M., Brülisauer, S., Gasca-Ruchti, A., Giacomelli, N., Grolimund, E., Kodjadjiku, U., Kulli, S., Mombelli, T., Nagarajan, S., Nobs, L., Papparella, M., Piguet, A., Ribeli-Hofmann, S., Martinez, V. R., Sasse, T., Roux, S., Schneider, M., Troesch, S., Vagenknecht, P., Wiedemann, M., Tsourti, Z., Dimopoulou, G., Zygoura, P., Vervita, K., Dellaporta, T., Fernández, M., Benito, L., Busquet, S., Pereira, E., Moser, Z. M., Rentsch, P., Oulkhouir, Y., Cloarec, N., Piovano, P. L., Nadal, E., Iranzo, P., Sala, M. A., Salamero, M. C., Dómine, M., Castro, R. L., Martínez, J. M., Cerciello, F., Addeo, A., Froesch, P., & Bettini, A. (2026). Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(26)00203-1

Source records

crossref · retrieved 2026-11-04T06:33:33.526Z